Lutetium-177 PSMA

Clinical Experience of 100 Consecutive Men Treated with Lu-177 

At the ESMO  2018 Conference that was recently concluded, there was a report of the clinical experience of 100 men with metastatic castrate resistant prostate cancer (mCRPC) who were consecutively treated with Lu-177 PSMA-I&T Radioligand Therapy. 

177Lu-PSMA-617 Clinical Trials

Endocyte, Inc. announced that it has enrolled the first man into its phase 3 VISION study of 177Lu-PSMA-617 as a clinical therapy.  Cancer ABCs has had a number of men asking about the trial.

VISION is an open-label, randomized trial assessing the addition of radiolabeled prostate-specific membrane antigen to standard therapy for PSMA-positive, previously treated metastatic castration-resistant prostate cancer (mCRPC). The study will enroll 750 men in total, with the primary endpoint being overall survival.

Currently, there are six different trials evaluating 177Lu-PSMA-617 actively recruiting men worldwide.  In the United States they are at Weill Cornell Medical Center in New York, UCLA in Los Angles, and one site in Houston Texas.  There are also trials in multiple locations in the UK, in Italy and in Australia.  For additional trial information and locations go to 

https://clinicaltrials.gov/ct2/results?term=177Lu-PSMA-617&Search=Search

Joel T. Nowak, MA, MSW wrote this Post.  Joel is the CEO/Executive Director of Cancer ABCs.  He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.